{
    "organizations": [],
    "uuid": "e6f6b2668266e5bf7f673204e236fbaaad7f187e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/lilly-results/drugmaker-eli-lilly-posts-quarterly-profit-idUSL3N1S1464",
    "ord_in_thread": 0,
    "title": "Drugmaker Eli Lilly posts quarterly profit",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " U.S. drugmaker Eli Lilly and Co reported a quarterly profit on Tuesday on higher demand for its newer treatments such as its diabetes drug Trulicity and psoriasis medicine Taltz.\nThe company reported net income of $1.22 billion, or $1.16 per share, in the first quarter ended March 31, compared with a loss of $110.8 million, or 10 cents per share, a year earlier.\nRevenue rose 9 percent to $5.70 billion. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila)\n ",
    "published": "2018-04-24T18:33:00.000+03:00",
    "crawled": "2018-04-25T14:28:09.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "drugmaker",
        "eli",
        "lilly",
        "co",
        "reported",
        "quarterly",
        "profit",
        "tuesday",
        "higher",
        "demand",
        "newer",
        "treatment",
        "diabetes",
        "drug",
        "trulicity",
        "psoriasis",
        "medicine",
        "taltz",
        "company",
        "reported",
        "net",
        "income",
        "billion",
        "per",
        "share",
        "first",
        "quarter",
        "ended",
        "march",
        "compared",
        "loss",
        "million",
        "cent",
        "per",
        "share",
        "year",
        "earlier",
        "revenue",
        "rose",
        "percent",
        "billion",
        "reporting",
        "akankshita",
        "mukhopadhyay",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ]
}